Bill Few Associates Inc. acquired a new stake in Pfizer Inc. (NYSE: PFE – Get Rating) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 74,288 shares of the biopharmaceutical company stock, valued at approximately $ 4,387,000. Pfizer comprises about 2.3% of Bill Few Associates Inc.’s investment portfolio, making the stock its 13th biggest position.
Several other large investors have also recently bought and sold shares of PFE. MJP Associates Inc. ADV boosted its stake in Pfizer by 18.9% during the fourth quarter. MJP Associates Inc. ADV now owns 19,458 shares of the biopharmaceutical company stock worth $ 1,102,000 after acquiring an additional 3,096 shares in the last quarter. Harrison & Co Wealth Management LLC bought a new position in Pfizer during the fourth quarter worth $ 1,455,000. Capital Advisors Inc. OK boosted its stake in Pfizer by 3.9% during the fourth quarter. Capital Advisors Inc. OK now owns 541,381 shares of the biopharmaceutical company stock worth $ 31,969,000 after acquiring an additional 20,514 shares in the last quarter. Xponance Inc. boosted its stake in Pfizer by 25.3% during the fourth quarter. Xponance Inc. now owns 521,138 shares of the biopharmaceutical company stock worth $ 30,773,000 after acquiring an additional 105,259 shares in the last quarter. Finally, Summit Trail Advisors LLC boosted its stake in Pfizer by 9.9% during the third quarter. Summit Trail Advisors LLC now owns 26,752 shares of the biopharmaceutical company stock worth $ 1,151,000 after acquiring an additional 2,400 shares in the last quarter. 66.50% of the stock is currently owned by institutional investors.
Shares of PFE stock opened at $ 46.53 on Friday. The firm has a 50-day moving average of $ 50.90 and a 200-day moving average of $ 52.34. The company has a market cap of $ 261.07 billion, a P / E ratio of 10.67, a P / E / G ratio of 0.59 and a beta of 0.76. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.39 and a quick ratio of 1.13. Pfizer Inc. has a one year low of $ 38.70 and a one year high of $ 61.71.
Pfizer (NYSE: PFE – Get Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $ 1.66 by ($ 0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The company had revenue of $ 25.66 billion for the quarter, compared to analysts’ expectations of $ 24.73 billion. During the same quarter last year, the business posted $ 0.93 EPS. The business’s quarterly revenue was up 76.8% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 6.62 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 10th. Investors of record on Friday, May 13th were issued a dividend of $ 0.40 per share. The ex-dividend date of this dividend was Thursday, May 12th. This represents a $ 1.60 dividend on an annualized basis and a yield of 3.44%. Pfizer’s dividend payout ratio (DPR) is presently 36.70%.
In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $ 50.00, for a total transaction of $ 1,645,400.00. Following the completion of the transaction, the executive vice president now owns 38,146 shares in the company, valued at $ 1,907,300. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $ 53.96, for a total transaction of $ 227,603.28. Following the transaction, the senior vice president now owns 10,846 shares of the company stock, valued at approximately $ 585,250.16. The disclosure for this sale can be found here. Insiders have sold 41,126 shares of company stock valued at $ 2,075,003 in the last quarter. Company insiders own 0.05% of the company stock.
Several research analysts have weighed in on the stock. JPMorgan Chase & Co. set a $ 57.00 price objective on shares of Pfizer in a report on Tuesday, May 3rd. SVB Leerink assumed coverage on shares of Pfizer in a report on Monday, May 23rd. They set a “market perform” rating and a $ 55.00 price objective on the stock. The Goldman Sachs Group set a $ 51.00 price objective on shares of Pfizer in a report on Wednesday, May 25th. Barclays set a $ 52.00 price objective on shares of Pfizer in a report on Tuesday, May 17th. Finally, Citigroup upped their price target on shares of Pfizer from $ 46.00 to $ 57.00 and gave the stock a “neutral” rating in a report on Tuesday, April 5th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $ 57.26.
About Pfizer: (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE: PFE – Get Rating).
Receive News & Ratings for Pfizer Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.